Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of bimekizumab in axial spondyloarthritis
CTR20211060Phase 3Completed
- Sponsor
- UCB
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of bimekizumab in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by UCB. Started Dec 2021; status: completed.
02
Drugs
bimekizumab
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on CTR20211060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211060.